INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
Search

All disclosures

Every ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.

Results

Data sources
SEC Form 46h ago
House PTR6h ago
SEC 13F6h ago
Robinhood Chain6h ago

Results

82,076 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
3
RR
Remer Eric RichardDirector, Chief Executive Officer
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$30K
2,797 sh
Feb 4, 2026
Page 1618 of 2052
← PrevNext →
Feb 4, 2026
traded Feb 4, 2026
+0d
SEC Form 4

Evidence

3
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$50K
4,844 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
MC
Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
OLMAOlema Pharmaceuticals, Inc.
Grant or award
A—
250.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
MC
Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
OLMAOlema Pharmaceuticals, Inc.
Grant or award
A—
106.3K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
HK
Holleran KevinDirector, President and CEO
HAYWHayward Holdings, Inc.
Option exercise · 10b5-1 plan
M$73K
52.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
AJ
Allaire JeremyDirector, Chairman and CEO
CRCLCircle Internet Group, Inc.
Option exercise
M—
6,742 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
AJ
Allaire JeremyDirector, Chairman and CEO
CRCLCircle Internet Group, Inc.
Option exercise
M—
6,017 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
AJ
Allaire JeremyDirector, Chairman and CEO
CRCLCircle Internet Group, Inc.
Option exercise
M—
15.2K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

1
BM
Barrett David MichaelDirector, Chief Executive Officer
EXFYExpensify, Inc.
Open-market sale · 10b5-1 plan
SELL$44K
30.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

1
VV
Vultaggio VincentPAO and PFO
ZNTLZentalis Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$1,398
556 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

1
SN
Sieffert Kristen NPresident
FOAFinance of America Companies Inc.
Open-market sale · 10b5-1 plan
SELL$17K
750 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

1
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$75K
381 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$1,626
156 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
FA
Fang AndyDirector
DASHDoorDash, Inc.
Other acquisition or disposition · 10b5-1 plan
J—
10.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
OO
Okupe OluyemiChief Financial Officer
HIMSHims & Hers Health, Inc.
Option exercise · 10b5-1 plan
M—
5,262 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

0
TS
Tang StanleyDirector
DASHDoorDash, Inc.
Other acquisition or disposition · 10b5-1 plan
J—
45.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$156K
15.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
15.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
HK
Holleran KevinDirector, President and CEO
HAYWHayward Holdings, Inc.
Option exercise · 10b5-1 plan
M—
52.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
TS
Tang StanleyDirector
DASHDoorDash, Inc.
Other acquisition or disposition · 10b5-1 plan
J—
45.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$4,499
23 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$7,449
39 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
156 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
WS
Wampler Kira SchererDirector
DOCSDoximity, Inc.
Derivative conversion · 10b5-1 plan
C—
2,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
WS
Wampler Kira SchererDirector
DOCSDoximity, Inc.
Option exercise · 10b5-1 plan
M—
2,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
AL
Alpern Paul LVP and General Counsel
AIPArteris, Inc.
Option exercise · 10b5-1 plan
M$2,800
5,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
FA
Fang AndyDirector
DASHDoorDash, Inc.
Other acquisition or disposition · 10b5-1 plan
J—
10.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
OO
Okupe OluyemiChief Financial Officer
HIMSHims & Hers Health, Inc.
Option exercise · 10b5-1 plan
M$26K
5,262 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$192
1 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
AL
Alpern Paul LVP and General Counsel
AIPArteris, Inc.
Option exercise · 10b5-1 plan
M—
5,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
WS
Wampler Kira SchererDirector
DOCSDoximity, Inc.
Derivative conversion · 10b5-1 plan
C—
2,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,844 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$4,535
23 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
WS
Wampler Kira SchererDirector
DOCSDoximity, Inc.
Option exercise · 10b5-1 plan
M—
2,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

41
MJ
Malm JoshuaCFO
FEAM5E Advanced Materials, Inc.
Open-market purchase
BUY$7,500
3,750 sh
Feb 2, 2026Feb 3, 2026
traded Feb 2, 2026
+1dSEC Form 4

Evidence

37
RJ
Running Michael J.Regional President - AMER
PLXSPLEXUS CORP
Open-market sale
SELL$190K
926 sh
Feb 2, 2026Feb 3, 2026
traded Feb 2, 2026
+1dSEC Form 4

Evidence

36
WR
Wilcox Jon RDirector
MCHBMechanics Bancorp
Grant or award
A—
2,554 sh
Sep 2, 2025Feb 3, 2026
traded Sep 2, 2025
+154dSEC Form 4

Evidence

33
DB
Dechairo BryanChief Operating Officer
WGSGeneDx Holdings Corp.
Open-market sale
SELL$117K
1,166 sh
Feb 2, 2026Feb 3, 2026
traded Feb 2, 2026
+1dSEC Form 4

Evidence

33
DB
Dechairo BryanChief Operating Officer
WGSGeneDx Holdings Corp.
Open-market sale
SELL$165K
1,662 sh
Feb 2, 2026Feb 3, 2026
traded Feb 2, 2026
+1dSEC Form 4

Evidence

30
MJ
Meade Christopher J.General Counsel and CLO
BLKBlackRock, Inc.
Tax withholding
F$3.89M
3,475 sh
Jan 30, 2026Feb 3, 2026
traded Jan 30, 2026
+4dSEC Form 4

Evidence